کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
4263413 | 1284621 | 2006 | 6 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Clinical Trial of Tripterygium Wilfordii Hook F. in Human Kidney Transplantation in China Clinical Trial of Tripterygium Wilfordii Hook F. in Human Kidney Transplantation in China](/preview/png/4263413.png)
ObjectiveIn this study, the effects of Triptergium Wilfordii Hook F.(T II) were assessed on human kidney allograft rejection and long-term survival.MethodsThis study compared treatment with T II(T II group, n = 121) to that without T II(control group, n = 102) among adult first cadaveric renal transplant recipients. The T II cohort of 121 recipients were divided into a regular dosage group (n = 82) and a double dosage group (n = 39). No antibody induction was administered to any patient.ResultsBiopsy-proven early acute allograft rejection occurred in 4.1% of patients in the T II group versus 24.5% of patients in the control group. No rejection or repeated rejections occurred in the double dosage group at 3 months after transplantation. Acute rejection episodes were milder in the T II than the control group. The incidence of CD25+ cells >10/ mm3 in the allografts at 3 months after transplantation was lower in the T II group than the control group, 15% and 50%, respectively. All patients tolerated T II well over the 5 years of this study. The 5-year graft survival censored for death with function was 96.7% in the T II group and 80.4% in the control group.ConclusionT II was effective to prevent renal allograft rejection and increase long-term renal allograft survival among adult cadaveric renal transplant recipients.
Journal: Transplantation Proceedings - Volume 38, Issue 5, June 2006, Pages 1274–1279